Teachers Retirement System of The State of Kentucky Makes New $1.04 Million Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

Teachers Retirement System of The State of Kentucky purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 44,450 shares of the biopharmaceutical company's stock, valued at approximately $1,039,000.

Several other institutional investors have also recently made changes to their positions in TGTX. NBC Securities Inc. raised its position in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 485 shares during the last quarter. Blue Trust Inc. raised its stake in TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock worth $35,000 after purchasing an additional 849 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in TG Therapeutics in the second quarter valued at approximately $35,000. ORG Wealth Partners LLC acquired a new position in shares of TG Therapeutics in the 3rd quarter valued at $53,000. Finally, Values First Advisors Inc. purchased a new stake in TG Therapeutics in the 3rd quarter valued at about $58,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Stock Down 0.4 %

NASDAQ TGTX traded down $0.12 during trading hours on Thursday, hitting $30.95. 1,982,969 shares of the company were exchanged, compared to its average volume of 3,589,588. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The firm has a market cap of $4.82 billion, a price-to-earnings ratio of -309.47 and a beta of 2.25. The company has a 50 day moving average of $29.24 and a two-hundred day moving average of $23.74. TG Therapeutics, Inc. has a 52-week low of $12.84 and a 52-week high of $36.84.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business's quarterly revenue was down 49.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.73 earnings per share. Equities research analysts anticipate that TG Therapeutics, Inc. will post 0.17 earnings per share for the current year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares of the company's stock, valued at $3,049,935.80. The trade was a 4.75 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 10.50% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on TGTX. HC Wainwright lifted their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday, November 5th. The Goldman Sachs Group raised their price target on TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, December 14th. JPMorgan Chase & Co. lifted their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a research report on Monday, November 25th. Finally, TD Cowen started coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a "buy" rating and a $50.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.